ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 Phase III APPLY-PNH Study: Oral Monotherapy With Iptacopan Has Superior Efficacy to SoC Eculizumab/Ravulizumab & Favorable Safety in Pts With PNH and Residual Anemia
By
ASH 2022 Conference Coverage
FEATURING
Regis de Latour
By
ASH 2022 Conference Coverage
FEATURING
Regis de Latour
0 views
December 20, 2022
Comments 0
Login to view comments.
Click here to Login
Benign Hematology